Opko Health Inc (OPK) Stock Price, Quote & News

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 305 575 4100

Website: www.opko.com

Address:

4400 Biscayne Boulevard, Miami, United States

Gasbagger Jun. 25 at 2:42 AM

$OPK Imagine ModeX pays that big fat lease every month for that Lab and nothing that is worth anything to shareholders has ever been produced out of it.

0 · Reply

tymtested Jun. 25 at 2:00 AM

$OPK Rayaldee in China will be HUGE! All signs are pointing UP! Labs profitable, Ngenla royalties growing, Rayaldee USA holding strong, Merck milestones, ENTX collaboration, stock buyback DARMA funding, international business contributing strong etc etc etc, oh, and several ModeX projects progressing nicely through R&D pipe! More earnings, more stock buybacks ( I hope)

0 · Reply

Mactoast Jun. 24 at 8:08 PM

$OPK Nope. Just the tip if turd mountain!

0 · Reply

Brasil07 Jun. 24 at 7:55 PM

$OPK It can depend by the level that algorithm afford the run of Opko...

0 · Reply

Gasbagger Jun. 24 at 7:11 PM

$OPK Buyers Beware ! Philip Frost only cares about himseld and his own pocket !

0 · Reply

TommyCotton Jun. 24 at 5:18 PM

$OPK is that the tip of $2 I can see from here?

0 · Reply

Gasbagger Jun. 23 at 8:13 PM

$OPK ENTX must have payed real close attention in Pump and Dump Class . Every trade made on June 22 should be investigated by the SEC. I thought Frost couldnt be asssociated with these type off stocks according to the deal he made with the SEC?

0 · Reply

Gasbagger Jun. 23 at 7:30 PM

$OPK Frost hasnt bought any stock in 7 months because in my opinion,because him and his friends were the bondholders. There to busy selling their 124 million shares they received. For that toxic funding they okayed.

0 · Reply

Mactoast Jun. 23 at 1:21 PM

$OPK Yay more options granted for all the losers who call themselves managment.

0 · Reply

tymtested Jun. 22 at 8:21 PM

$OPK opko owns a few ENTX shares

1 · Reply

OPKO Health Transcript: AGM 2026

2026-06-16T13:36:09.000Z - 8 days ago

Entera Bio and Opko Health present preclinical data for oral peptides

ENTX

Jun 15, 2026, 8:00 AM EDT - 9 days ago

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Jun 3, 2026, 4:20 PM EDT - 21 days ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2026

May 15, 2026, 8:00 AM EDT - 5 weeks ago

OPKO Health Proxy statement: Proxy filing

May 12, 2026, 8:00 AM EDT - 6 weeks ago

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

May 8, 2026, 7:00 AM EDT - 6 weeks ago

OPKO Health Slides: Corporate presentation

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

OPKO Health Proxy statement: Proxy filing

2026-04-29T12:37:59.000Z - 2 months ago

Opko Health downgraded to Market Perform from Outperform at Barrington

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Quarterly report: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 2 months ago

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Apr 22, 2026, 8:00 AM EDT - 2 months ago

OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Apr 21, 2026, 4:05 PM EDT - 2 months ago

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-02T14:20:11.000Z - 4 months ago

Opko Health price target lowered to $1.50 from $2.25 at Barrington

Feb 27, 2026, 8:00 AM EST - 4 months ago

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Earnings release: Q4 2025

Feb 26, 2026, 4:05 PM EST - 4 months ago

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Feb 12, 2026, 8:00 AM EST - 4 months ago

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

2026-02-04T13:16:35.000Z - 5 months ago

Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet

ENTX

Feb 4, 2026, 8:00 AM EST - 5 months ago

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Jan 14, 2026, 4:30 PM EST - 5 months ago

OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:11 PM EST - 6 months ago

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 7 months ago

OPKO Health Slides: Corporate presentation

2025-11-20T09:50:09.000Z - 7 months ago

Opko Health initiated with a Neutral at JPMorgan

Nov 19, 2025, 4:05 PM EST - 7 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-10-30T20:10:16.000Z - 8 months ago

Opko Health downgraded to Hold from Buy at Jefferies

2025-10-29T20:36:22.000Z - 8 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)

Oct 29, 2025, 4:30 PM EDT - 8 months ago

OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

OPKO Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

OPKO Health Earnings release: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 8 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

2025-10-29T12:10:25.000Z - 8 months ago

Opko Health’s ModeX enters license, collab agreement with Regeneron

REGN

2025-10-28T12:21:29.000Z - 8 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004

Oct 22, 2025, 4:05 PM EDT - 8 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

2025-09-22T12:00:42.000Z - 9 months ago

Opko Health management to meet with Barrington

Sep 15, 2025, 8:30 AM EDT - 10 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Earnings release: Q2 2025

Jul 31, 2025, 4:05 PM EDT - 11 months ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jun 30, 2025, 8:01 AM EDT - 1 year ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

Jun 25, 2025, 11:00 AM EDT - 1 year ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

2025-06-25T12:10:46.000Z - 1 year ago

Entera Bio, Opko Health announce new in vivo data for OPK-88006

ENTX

2025-06-25T12:10:37.000Z - 1 year ago

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

ENTX

2025-06-09T12:21:02.000Z - 1 year ago

Opko Health’s ModeX forms Scientific Advisory Board

Jun 4, 2025, 11:05 AM EDT - 1 year ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 9:00 AM EDT - 1 year ago

OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

OPKO Health to Participate in Two Upcoming Investor Conferences

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q1 2025

2025-04-25T09:15:19.000Z - 1 year ago

Opko Health initiated with a Neutral at JPMorgan

2025-04-04T12:10:48.000Z - 1 year ago

Opko Health board authorizes $100M increase to existing share repurchase program

Apr 4, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

2025-03-25T18:57:10.000Z - 1 year ago

Opko Health management to meet with Piper Sandler

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q4 2024

Feb 27, 2025, 4:10 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Slides: FY 2025

Jan 9, 2025, 11:45 AM EST - 1 year ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:30 PM EST - 1 year ago

OPKO Health Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q3 2024

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 1 year ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Aug 30, 2024, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q2 2024

Aug 7, 2024, 4:06 PM EDT - 2 years ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 4:14 PM EDT - 2 years ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jun 6, 2024, 10:30 AM EDT - 2 years ago

OPKO Health Transcript: Jefferies 2024 Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 2 years ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 3, 2024, 8:00 AM EDT - 2 years ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 5, 2024, 8:52 AM EST - 2 years ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Feb 29, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q4 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 22, 2024, 4:05 PM EST - 2 years ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 16, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Jan 10, 2024, 6:45 PM EST - 2 years ago

OPKO Health Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 7, 2023, 6:45 AM EST - 2 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Quarterly report: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q3 2023

Nov 6, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 2, 2023, 10:00 AM EDT - 2 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 25, 2023, 4:25 PM EDT - 2 years ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Sep 28, 2023, 4:08 PM EDT - 2 years ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Quarterly report: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings release: Q2 2023

Jul 25, 2023, 4:05 PM EDT - 3 years ago

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Gasbagger Jun. 25 at 2:42 AM

$OPK Imagine ModeX pays that big fat lease every month for that Lab and nothing that is worth anything to shareholders has ever been produced out of it.

0 · Reply

tymtested Jun. 25 at 2:00 AM

0 · Reply

Mactoast Jun. 24 at 8:08 PM

$OPK Nope. Just the tip if turd mountain!

0 · Reply

Brasil07 Jun. 24 at 7:55 PM

$OPK It can depend by the level that algorithm afford the run of Opko...

0 · Reply

Gasbagger Jun. 24 at 7:11 PM

$OPK Buyers Beware ! Philip Frost only cares about himseld and his own pocket !

0 · Reply

TommyCotton Jun. 24 at 5:18 PM

$OPK is that the tip of $2 I can see from here?

0 · Reply

Gasbagger Jun. 23 at 8:13 PM

0 · Reply

Gasbagger Jun. 23 at 7:30 PM

0 · Reply

Mactoast Jun. 23 at 1:21 PM

$OPK Yay more options granted for all the losers who call themselves managment.

0 · Reply

tymtested Jun. 22 at 8:21 PM

$OPK opko owns a few ENTX shares

1 · Reply

tradertrash Jun. 22 at 7:10 PM

$OPK entx up 36% thx for noth'n frosty

0 · Reply

tradertrash Jun. 22 at 6:55 PM

$OPK is this the most hated stock by the Mkt❓ ol frosty has done a great job 👍

0 · Reply

Gasbagger Jun. 22 at 5:33 PM

$OPK Frost invested his own personal money into the COCP R&D hustle. He is a 10 percent owner of COCP. He then takes Opko's shareholders investment in Opko and invests it in COCP and loses 90 percent of it. Just another example of screwing shareholder's out of their investment.

0 · Reply

Liorkd Jun. 22 at 4:31 PM

$OPK wow entx exploding

1 · Reply

tradertrash Jun. 22 at 2:23 PM

$OPK serious money for mgt, just a big joke for sh

0 · Reply

Brasil07 Jun. 22 at 2:22 PM

$OPK Opko Is really a Nightmare for all the people that have a disgrace to be a shareholders, I never saw in my Life a shit like this...

0 · Reply

tradertrash Jun. 22 at 2:22 PM

$OPK good news it dropped .o6 cents 😆 it just gets run back thru r&d rinse&repeat, nothing news or new here

0 · Reply

Indyshaw Jun. 22 at 1:00 PM

$OPK $ENTX Just got amazing FDA news.

0 · Reply

Gasbagger Jun. 20 at 9:37 PM

$OPK MDX2004 is a rehash from 2016 . It didn't work then and they know it won't work now. It's just an R&D money grab.

1 · Reply

TommyCotton Jun. 20 at 3:54 PM

$OPK not great—but better.

0 · Reply

tymtested Jun. 18 at 10:08 PM

$OPK

0 · Reply

tymtested Jun. 18 at 6:28 PM

$OPK YTD, OPKO is performing equal to the NASDAQ!! aaannndd, OPKO is headed up!

0 · Reply

Market Cap	1.10B
Revenue (ttm)	606.88M
Net Income (ttm)	-225.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37.19%
Debt to Equity Ratio	0.21

Volume	2,370,900
Avg Vol	2,607,166
Day's Range	N/A - N/A
Shares Out	755.09M
Stochastic %K	82%
Beta	1.50
Analysts	Sell
Price Target	$2.58